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PRESENTATION
A 60-year-old woman with diabetes and
hypertension presented with a decreased vision
OD to 6/18 N10 due to cystoid macular edema
(CME) following vitrectomy for removal of the
dislocated posterior chamber intraocular lens
(PCIOL) and scleral-fixated intraocular lens (SFIOL)
implantation performed five months before.
Spectral domain optical coherence tomography
(SD-OCT) showed a central foveal thickness (CFT)
of 484 µm. Intravitreal ranibizumab (LUCENTIS®;
Genentech, Inc) was administered; however, the
CFT increased to 533 µm after one month. She
received intravitreal dexamethasone (DEX) implant
(Ozurdex®, Allergan Inc.), which resulted in best
corrected visual acuity (BCVA) improvement to
6/12 N10 and CFT reduction to 404 µm within
a month. Three months later, CFT increased
again to 677 µm and she received a second DEX
implant. Seven weeks following the injection, she
presented with pain, corneal haze, and intraocular
pressure (IOP) of 38 mmHg. A week later, IOP
decreased to 16 mmHg on brimonidine tartrate
0.2% and timolol maleate 0.5% BD; however, the
DEX implant was seen in the anterior chamber
(Figure 1a). Complete pupillary dilatation in this
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vitrectomized eye allowed the implant to migrate
forward through the gap between the IOL edge and
the pupil (Figure 1b).
There was no corneal edema and BCVA was
maintained at 6/12 N10. Specular microscopy
showed an endothelial count (EC) of 1144
cells/mm2 (Figure 1c). SD-OCT revealed a
CFT of 365 μm (Figure 1d). A trial of wide
pupillary dilatation with supine position failed
to reposition the implant into the vitreous
cavity. Pros and cons of implant removal
were discussed and patient opted for weekly
follow-up. Corneal clarity was maintained,
EC was 1106, 1181, 1193, and 1205 cells/mm2
at each weekly visit, respectively, and IOP
remained <20 mmHg without treatment. Within
a month, the implant disappeared from the
anterior chamber, although the CFT increased
again to 711 µm. Due to the recent anterior
migration of DEX implant, three monthly doses
of intravitreal ranibizumab were administered.
Suboptimal visual and anatomical results led
us to inject DEX implant again, with care taken
not to dilate the pupil fully at any time. She
underwent four intravitreal DEX implants over
the following year; BCVA remained stable at
6/12 N8 with a clear cornea, IOP < 20 mmHg
in the absence of therapy, no recurrence
of CME, and no anterior migration of the
implant.
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Figure 1. (a) Clinical photograph of the right eye showing a clear cornea, scleral-fixated posterior chamber intraocular lens (SFIOL)
in situ, and an intravitreally administered dexamethasone (DEX) implant lying inferiorly in the anterior chamber. (b) A gap between
the IOL edge and pupil margin could be seen in upgaze (white arrow). (c) Endothelial count of the right eye performed on the
same day. (d) Spectral domain optical coherence tomography (SD-OCT) showing mild macular edema and hard exudates.
DISCUSSION
Intravitreal DEX implant is a safe and effective
therapeutic option for post-surgical macular
edema.[1] Anterior chambermigration of the implant
is a potential, though uncommon complication,
in eyes with a compromised lens capsule, prior
to vitrectomy and/or iris defects.[2, 3] Very few
cases of migration in eyes with an SFIOL have
been reported,[2, 4, 5] as has occurred in this case,
reinforcing that the presence of an IOL alone
does not prevent the implant migration when the
posterior capsule is not intact. As a precaution to
minimize recurrent migration, the pupil size was
kept reduced enough to cover the edge of the
optic.
Corneal endothelial decompensation is themost
serious complication resulting from the migration
of implant into the anterior chamber.[1, 4] Early
migration (within three weeks of injection) could
result in higher incidence of corneal edema as
higher rigidity of the implant in the first weeks could
cause greater mechanical endothelial trauma.[2]
This would explain why our patient did not develop
corneal edema and could avoid the additional
procedure of immediate repositioning or removing
the implant, which reduces the likelihood of
permanent corneal edema.[2, 3]
While vitrectomized eyes without an intact lens
capsule are at risk for anterior migration of a DEX
implant, this subset of patients may also benefit
most from having a DEX implant administered
for post-surgical macular edema. A regular post-
injection follow-up can recognize and manage
this rare, though potentially vision threatening,
complication at the earliest. An individualized
approach is recommended that takes into account
the potential anterior segment complications as
well as loss of drug effectiveness. A single episode
of anterior chamber migration of the DEX implant
should not be considered as a contraindication for
further injections if warranted.
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